ACALABRUTINIB
acalabrutinib 100 mg tablet, 56
ACALABRUTINIB (13810W)
13810W
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: First line drug treatment of this indication - in combination with obinutuzumab
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 6 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||